10-Q: Alzamend Neuro Faces Going Concern Amid Rising Losses

Alzamend Neuro reported increased net losses and a 'going concern' warning, despite progress in its AL001 clinical trials and a recent capital raise.

Summary

• Alzamend Neuro, a clinical-stage biopharmaceutical company, reported a net loss of $3.7 million for the six months ended October 31, 2025, a 59% increase from $2.3 million in the same period last year.
• The company's cash position as of October 31, 2025, was $4.4 million, with working capital of $4.0 million and an accumulated deficit of $62.2 million.
• Research and development expenses significantly increased by 270% to $1.9 million for the six months ended October 31, 2025, primarily due to a Phase IIA brain imaging study for AL001 with Massachusetts General Hospital.
• General and administrative expenses remained relatively stable at $1.8 million, though legal fees surged due to issues related to the termination of a CRO contract for the ALZN002 clinical trial.
• The company completed the clinical portion of its Phase II study for AL001 in healthy human subjects in November 2025, with topline data expected in Q1 2026.
• The contract with Biorasi, LLC, the CRO for the ALZN002 Phase I/IIA clinical trial, was terminated in February 2024, and the company is actively seeking a replacement.
• Management has identified a material weakness in internal control over financial reporting due to insufficient accounting department resources, which restricts adequate reviews and approvals.
• Alzamend Neuro raised $4.0 million through the sale of Series C Convertible Preferred Stock during the six months ended October 31, 2025.

Sentiment

Score: 3

Explanation: The sentiment is negative due to a significant increase in net losses, an explicit 'going concern' warning, and a major setback with the termination of the CRO contract for the ALZN002 clinical trial, leading to increased legal costs and delays. While there is some progress with AL001, the overall financial health and operational challenges for ALZN002 overshadow these positives.

Positives

• Completed the clinical portion of the Phase II study for AL001 in healthy human subjects in November 2025, with topline data anticipated in Q1 2026.
• Nonclinical studies for AL001 showed lower plasma lithium levels and consistently higher lithium concentrations in brain tissues compared to lithium carbonate, suggesting an enhanced safety profile and potential for lower dosing.
• Successfully identified a Maximum Tolerated Dose (MTD) for AL001 (240 mg TID lithium carbonate equivalent) designed to potentially eliminate the need for therapeutic drug monitoring (TDM).
• Secured $4.0 million in net proceeds from the issuance of Series C Convertible Preferred Stock during the six months ended October 31, 2025.
• Net cash used in operating activities decreased to $3.5 million for the six months ended October 31, 2025, compared to $4.5 million in the prior year period.

Negatives

• Net loss increased by 59% to $3.7 million for the six months ended October 31, 2025, compared to the same period last year.
• The company explicitly stated 'substantial doubt about our ability to continue as a going concern' due to recurring losses and insufficient cash to fund operations for the next twelve months.
• The company received notice in February 2024 that Biorasi, LLC, the CRO for the ALZN002 clinical trial, was terminating its contract, leading to delays and increased legal fees.
• Management believes the achievement of the second performance condition for ALZN002 (completion of Phase II clinical trial) is not probable as of October 31, 2025.
• Legal fees significantly increased due to actions by the CRO from the termination of the ALZN002 clinical trial.
• The company has an accumulated deficit of $62.2 million as of October 31, 2025.
• The company has identified a material weakness in its internal control over financial reporting due to insufficient accounting department resources, which has not yet been remediated.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring net losses and insufficient cash to fund operations for the next twelve months.
• Inability to raise additional capital could force delays, reductions, or elimination of research and development programs and planned clinical trials.
• The termination of the CRO contract for ALZN002 creates uncertainty and potential delays in its clinical development.
• The company relies heavily on third-party licenses for its product candidates, and failure to meet milestones could lead to license termination.
• The company has not generated any product revenue to date and expects to incur net losses for the foreseeable future.
• The material weakness in internal control over financial reporting could lead to undetected material misstatements in financial statements.

Future Outlook

Management expects to continue incurring net losses for the foreseeable future and will require additional capital to fund development and commercial operations. The company plans to initiate five new clinical trials for AL001 in collaboration with Massachusetts General Hospital and expects topline data from the AL001 Phase II study in healthy human subjects in Q1 2026. A replacement CRO is being sought for the ALZN002 clinical trial. The 2025 Stock Incentive Plan, subject to stockholder approval, aims to provide equity incentives.

Management Comments

• Management expects to continue to incur losses for the foreseeable future and needs to raise additional capital until it is able to generate revenues from operations sufficient to fund its development and commercial operations.
• These factors create substantial doubt about our ability to continue as a going concern.
• If the Company is unable to obtain funding, it could be required to delay, reduce or eliminate research and development programs and planned clinical trials which could adversely affect the Company’s business operations.
• The increase in legal fees, which accounted for a significant proportion of the increase, was a result of actions by the CRO from the termination of our ALZN002 clinical trial.

Industry Context

Alzamend Neuro operates in the highly competitive and capital-intensive biopharmaceutical sector, specifically targeting neurodegenerative and psychiatric disorders like Alzheimer's, bipolar disorder, MDD, and PTSD. The company's AL001 candidate, a novel lithium formulation, aims to address the limitations of existing lithium treatments by improving safety and brain bioavailability, potentially redefining treatment practices. The ALZN002 candidate represents an active immunotherapy approach, contrasting with passive immunization strategies common in Alzheimer's research. The need for substantial capital and the inherent risks of clinical development are typical for companies at this stage, especially given the high failure rates and long timelines in CNS drug development.

Comparison to Industry Standards

• AL001's preclinical data showing lower plasma lithium levels and higher brain concentrations compared to lithium carbonate suggests a potential advantage over the 'gold standard' lithium salts, which often require therapeutic drug monitoring (TDM) due to a narrow therapeutic window. This could position AL001 favorably against current treatments for BD, MDD, and PTSD.
• The company's active immunotherapy approach with ALZN002, using autologous DCs, aims to offer a more robust and long-lasting effect on amyloid clearance compared to passive immunization treatments (e.g., monoclonal antibodies) used by competitors, potentially with a safer profile due to reliance on the patient's own immune components. Specific comparable companies or projects are not detailed in the filing, but the general comparison to 'passive immunization treatment approaches' is noted.

Corporate Governance

Legal Proceedings

• The company is not currently a party to or aware of any legal proceedings that are believed to have a material adverse effect on its business, financial condition, or results of operations.
• Increased legal fees were incurred due to actions by the CRO from the termination of the ALZN002 clinical trial, indicating potential disputes or negotiations related to the contract termination.

Related Party Transactions

• Ault Lending, LLC, a related party due to common management, entered into a securities purchase agreement for Series B Convertible Preferred Stock and warrants. The agreement terminated as the final closing did not occur by March 31, 2025.
• Ault Lending converted 2,100 shares of Series B Convertible Preferred Stock into 905,172 shares of Common Stock during the six months ended October 31, 2025.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from future equity raises and reverse stock splits. The 'going concern' warning and increased losses could negatively impact share price. However, progress in AL001 trials offers potential long-term value.
• **Employees**: Stock-based compensation plans are in place to incentivize, but the company's financial instability and need for capital could create uncertainty.
• **Customers (Future Patients)**: Delays in ALZN002 clinical trials mean a longer wait for potential treatments. Progress in AL001 offers hope for new therapeutic options for Alzheimer's, BD, MDD, and PTSD.
• **Creditors**: The 'going concern' warning indicates increased risk for current and potential creditors.
• **Licensor (University of South Florida Research Foundation)**: Continued development and potential commercialization of AL001 and ALZN002 are crucial for future royalty and milestone payments. Failure to meet milestones could lead to license termination.

Next Steps

• Report topline data from the AL001 Phase II study in healthy human subjects in the first quarter of 2026.
• Initiate five new clinical trials for AL001 in collaboration with Massachusetts General Hospital to determine relative increased lithium levels in the brain for Alzheimers, BD, MDD, and PTSD.
• Engage a replacement CRO for the ALZN002 Phase I/IIA clinical trial.
• Seek stockholder approval for the 2025 Stock Incentive Plan.
• Raise additional funds through public equity, private equity, and debt financings to support ongoing operations and clinical development.

Key Dates

Recommendation

The company faces significant financial distress, evidenced by a substantial increase in net losses and an explicit 'going concern' warning, indicating a high risk of insolvency without further capital. The operational setback with the termination of the ALZN002 CRO contract, leading to increased legal fees and delays, further compounds the negative outlook. While AL001 shows some clinical progress, the overall financial instability, reliance on continuous capital raises, and material weakness in internal controls present a highly speculative investment. A seasoned investor would likely view these factors as strong indicators to sell or avoid the stock due to the elevated risk profile and uncertain path to profitability.

Keywords

Alzamend Neuro, ALZN, Alzheimer's disease, bipolar disorder, major depressive disorder, post-traumatic stress disorder, AL001, ALZN002, clinical trial, biopharmaceutical, SEC filing, 10-Q, going concern, drug development, neurodegenerative diseases, psychiatric diseases, lithium cocrystal, immunotherapy vaccine, Massachusetts General Hospital